Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Cash from Operations (2017 - 2026)

Denali Therapeutics has reported Cash from Operations over the past 9 years, most recently at 98538000.0 for Q4 2025.

  • Quarterly Cash from Operations fell 17.71% to 98538000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 412600000.0 through Dec 2025, down 18.67% year-over-year, with the annual reading at 412600000.0 for FY2025, 18.67% down from the prior year.
  • Cash from Operations was 98538000.0 for Q4 2025 at Denali Therapeutics, up from 107296000.0 in the prior quarter.
  • Over five years, Cash from Operations peaked at 41434000.0 in Q3 2021 and troughed at 131468000.0 in Q1 2025.
  • The 5-year median for Cash from Operations is 73980500.0 (2022), against an average of 78719500.0.
  • Year-over-year, Cash from Operations tumbled 48279.07% in 2021 and then skyrocketed 32.31% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 65494000.0 in 2021, then fell by 10.95% to 72663000.0 in 2022, then tumbled by 35.77% to 98657000.0 in 2023, then increased by 15.15% to 83715000.0 in 2024, then fell by 17.71% to 98538000.0 in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Cash from Operations are 98538000.0 (Q4 2025), 107296000.0 (Q3 2025), and 75298000.0 (Q2 2025).